A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL)

Stefano Molica, Diana Giannarelli, Luciano Levato, Rosanna Mirabelli, Massimo Gentile, Mirella Lentini, Fortunato Morabito

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We propose an algorithm based on a slightly modified version of MD Anderson Cancer Center (MDACC) score (i.e., mutational status of IgVH, LDH, presence of high-risk FISH abnormalities), β2-microglobulin and separation of clinical monoclonal B-cell lymphocytosis (cMBL) from chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT) of a prospective multicentre cohort including 83 cMBL and 136 CLL Rai stage 0 patients. Patients with MDACC score point ≥38, at any level of β2-microglobulin and irrespective of whether they fulfilled 2008 International Workshop on CLL (IWCLL) criteria for CLL Rai stage 0 or cMBL, experienced the worst clinical outcome (5-year TTFT, 24 %) and formed the high-risk group. In contrast, subjects with a diagnosis of cMBL, MDACC score point 2-microglobulin ≤ UNL had the best clinical outcome (5-year TTFT, 100 %) and constituted the low-risk group. The intermediate group included patients in Rai stage 0, MDACC score point 2-microglobulin, and patients with cMBL, MDACC score point 2-microglobulin ≥ UNL. Cases showing these features can be grouped together to form the intermediate-risk group (5-year TTFT, 65 %). Although the separation between cMBL and Rai stage 0, as proposed by the 2008 IWCLL guidelines, has clinical implications, the model we propose may help to classify patients with cMBL and Rai stage 0 into more precise subgroups suggesting that a prognostic separation of these entities based solely on clonal B-cell threshold may be unsatisfactory.

Original languageEnglish
Pages (from-to)290-295
Number of pages6
JournalInternational Journal of Hematology
Volume100
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Lymphocytosis
B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Neoplasms
Therapeutics
Education
Guidelines

Keywords

  • CLL
  • cMBL
  • Prognosis
  • TTFT

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL). / Molica, Stefano; Giannarelli, Diana; Levato, Luciano; Mirabelli, Rosanna; Gentile, Massimo; Lentini, Mirella; Morabito, Fortunato.

In: International Journal of Hematology, Vol. 100, No. 3, 2014, p. 290-295.

Research output: Contribution to journalArticle

@article{18b5d1abba3c49c3ab3be06b0b0c951f,
title = "A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL)",
abstract = "We propose an algorithm based on a slightly modified version of MD Anderson Cancer Center (MDACC) score (i.e., mutational status of IgVH, LDH, presence of high-risk FISH abnormalities), β2-microglobulin and separation of clinical monoclonal B-cell lymphocytosis (cMBL) from chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT) of a prospective multicentre cohort including 83 cMBL and 136 CLL Rai stage 0 patients. Patients with MDACC score point ≥38, at any level of β2-microglobulin and irrespective of whether they fulfilled 2008 International Workshop on CLL (IWCLL) criteria for CLL Rai stage 0 or cMBL, experienced the worst clinical outcome (5-year TTFT, 24 {\%}) and formed the high-risk group. In contrast, subjects with a diagnosis of cMBL, MDACC score point 2-microglobulin ≤ UNL had the best clinical outcome (5-year TTFT, 100 {\%}) and constituted the low-risk group. The intermediate group included patients in Rai stage 0, MDACC score point 2-microglobulin, and patients with cMBL, MDACC score point 2-microglobulin ≥ UNL. Cases showing these features can be grouped together to form the intermediate-risk group (5-year TTFT, 65 {\%}). Although the separation between cMBL and Rai stage 0, as proposed by the 2008 IWCLL guidelines, has clinical implications, the model we propose may help to classify patients with cMBL and Rai stage 0 into more precise subgroups suggesting that a prognostic separation of these entities based solely on clonal B-cell threshold may be unsatisfactory.",
keywords = "CLL, cMBL, Prognosis, TTFT",
author = "Stefano Molica and Diana Giannarelli and Luciano Levato and Rosanna Mirabelli and Massimo Gentile and Mirella Lentini and Fortunato Morabito",
year = "2014",
doi = "10.1007/s12185-014-1634-7",
language = "English",
volume = "100",
pages = "290--295",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL)

AU - Molica, Stefano

AU - Giannarelli, Diana

AU - Levato, Luciano

AU - Mirabelli, Rosanna

AU - Gentile, Massimo

AU - Lentini, Mirella

AU - Morabito, Fortunato

PY - 2014

Y1 - 2014

N2 - We propose an algorithm based on a slightly modified version of MD Anderson Cancer Center (MDACC) score (i.e., mutational status of IgVH, LDH, presence of high-risk FISH abnormalities), β2-microglobulin and separation of clinical monoclonal B-cell lymphocytosis (cMBL) from chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT) of a prospective multicentre cohort including 83 cMBL and 136 CLL Rai stage 0 patients. Patients with MDACC score point ≥38, at any level of β2-microglobulin and irrespective of whether they fulfilled 2008 International Workshop on CLL (IWCLL) criteria for CLL Rai stage 0 or cMBL, experienced the worst clinical outcome (5-year TTFT, 24 %) and formed the high-risk group. In contrast, subjects with a diagnosis of cMBL, MDACC score point 2-microglobulin ≤ UNL had the best clinical outcome (5-year TTFT, 100 %) and constituted the low-risk group. The intermediate group included patients in Rai stage 0, MDACC score point 2-microglobulin, and patients with cMBL, MDACC score point 2-microglobulin ≥ UNL. Cases showing these features can be grouped together to form the intermediate-risk group (5-year TTFT, 65 %). Although the separation between cMBL and Rai stage 0, as proposed by the 2008 IWCLL guidelines, has clinical implications, the model we propose may help to classify patients with cMBL and Rai stage 0 into more precise subgroups suggesting that a prognostic separation of these entities based solely on clonal B-cell threshold may be unsatisfactory.

AB - We propose an algorithm based on a slightly modified version of MD Anderson Cancer Center (MDACC) score (i.e., mutational status of IgVH, LDH, presence of high-risk FISH abnormalities), β2-microglobulin and separation of clinical monoclonal B-cell lymphocytosis (cMBL) from chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT) of a prospective multicentre cohort including 83 cMBL and 136 CLL Rai stage 0 patients. Patients with MDACC score point ≥38, at any level of β2-microglobulin and irrespective of whether they fulfilled 2008 International Workshop on CLL (IWCLL) criteria for CLL Rai stage 0 or cMBL, experienced the worst clinical outcome (5-year TTFT, 24 %) and formed the high-risk group. In contrast, subjects with a diagnosis of cMBL, MDACC score point 2-microglobulin ≤ UNL had the best clinical outcome (5-year TTFT, 100 %) and constituted the low-risk group. The intermediate group included patients in Rai stage 0, MDACC score point 2-microglobulin, and patients with cMBL, MDACC score point 2-microglobulin ≥ UNL. Cases showing these features can be grouped together to form the intermediate-risk group (5-year TTFT, 65 %). Although the separation between cMBL and Rai stage 0, as proposed by the 2008 IWCLL guidelines, has clinical implications, the model we propose may help to classify patients with cMBL and Rai stage 0 into more precise subgroups suggesting that a prognostic separation of these entities based solely on clonal B-cell threshold may be unsatisfactory.

KW - CLL

KW - cMBL

KW - Prognosis

KW - TTFT

UR - http://www.scopus.com/inward/record.url?scp=84927171719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927171719&partnerID=8YFLogxK

U2 - 10.1007/s12185-014-1634-7

DO - 10.1007/s12185-014-1634-7

M3 - Article

VL - 100

SP - 290

EP - 295

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -